Publications by authors named "A M Busschots"
Article Synopsis
- Lymphomatoid papulosis (LyP) is a rare skin disorder affecting T-cells, and there's limited information about its impact on children.
- A study analyzed data from 87 pediatric patients diagnosed with LyP over a 24-year period, noting that most cases were initially misdiagnosed and the average age at onset was 7 years.
- The prognosis appears positive, with a 100% overall survival rate, although 10% of patients had associated blood cancers, indicating a significantly higher risk of malignancy compared to the general youth population.
Genetic Stability of Driver Alterations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type and Their Relapses: A Rationale for the Use of Molecular-Based Methods for More Effective Disease Monitoring.
Cancers (Basel)
October 2022
Article Synopsis
- A study analyzed 73 biopsies from 57 PCDLBCL-LT patients using advanced genetic methods, revealing that 95% had significant genetic alterations associated with the disease.
- The ongoing presence of these genetic mutations suggests that targeted therapies could be developed, potentially enhancing patient monitoring and intervention strategies to improve outcomes for those with this challenging lymphoma.
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) and primary cutaneous follicle center lymphoma with a diffuse population of large cells (PCFCL-LC) are both primary cutaneous B-cell lymphomas with large-cell morphology (CLBCL) but with different clinical characteristics and behavior. In systemic diffuse large B-cell lymphoma, not otherwise specified (DLBCL-NOS), gene-expression profiling (GEP) revealed two molecular subgroups based on their cell-of-origin (COO) with prognostic significance: the germinal center B-cell-like (GCB) subtype and the activated B-cell-like (ABC) subtype. This study investigated whether COO classification is a useful tool for classification of CLBCL.
View Article and Find Full Text PDFBackground: The PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study is a prospective analysis of an international database. Here we examine front-line treatments and quality of life (QoL) in patients with newly diagnosed mycosis fungoides (MF).
Objectives: To identify (i) differences in first-line approaches according to tumour-nodes-metastasis-blood (TNMB) staging; (ii) parameters related to a first-line systemic approach and (iii) response rates and QoL measures.